NR1H4 and congenital secretory chloride diarrhea 1: OCA has been approved by the US Food and Drug Administration [123] and China Food and Drug Administration as the first steroid FXR agonist for treating patients with CLD who are not fully responsive to or intolerant of UDCA [124].